Shots:

• The companies have started testing BNT162b2 in children aged 6-11yrs. with initial results anticipated in H2’21. The companies are planning to expand the vaccination to that age range by early 2022
• The companies plan to initiate the safety of BNT162b2 (10/20/30µg) vs PBO in P-I/II trial in 144-participant
• Pfizer and BioNTech later plan to expand the trial to 4-500-participant to evaluate the safety- tolerability and immune response of the vaccine in kids. Meanwhile- Pfizer has been testing the vaccine in children from aged 12-15yrs. and anticipating results in coming weeks

 ­ Ref: Reuters | Image: WebMD